• Takeda announces results of Phase 3b VARSITY studies biospectrumasia
    May 20, 2019
    VARSITY is a Phase 3b, randomized, double-blind, double-dummy, multi-center, active-controlled study to evaluate the efficacy and safety of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) at week 52 in patients with moderately to sev
PharmaSources Customer Service